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Research Integrity Series
This is one article in an occasional PLoS
Medicine series on research integrity that
examines issues affecting the ethics of health
research worldwide.
Within international development [1],
public health [2], and clinical medicine
[3–5], there is increasing interest in
determining whether cash payments or
other economic incentives can be used to
influence the choices and behavior of
individuals and groups in order to pro-
mote desired health goals (Box 1). How-
ever, a number of complex issues affect the
review and approval by research ethics
committees (RECs) of research studying
the effectiveness of using financial incen-
tives to promote desired health goals.
Current ethical and regulatory frame-
works regard the provision of gifts or cash
payments to participants in human re-
search as potentially problematic. Specif-
ically, these frameworks imply that such
incentives may undermine the autonomy
of participant choice, hinder the disclosure
of medical information, exacerbate social
inequalities, or result in the exploitation
or degradation of vulnerable populations
[6–9]. Typically, these frameworks pro-
vide guidance about payment to research
participants to reimburse expenses, to
compensate for time and effort, to provide
insurance coverage, or as an incentive to
participate in the research itself. However,
the issue of payment as a component of
the research intervention is relatively new.
RECs thus lack explicit guidance about
ethical issues surrounding research that
evaluates the use of financial incentives as
an intervention to promote health.
We argue that when incentives are used
to promote healthy behavior there are
important cases in which common con-
cerns about the provision of incentives to
research participants do not apply, or do
not apply with the same force. In these
cases, focusing primarily on the size and
attractiveness of incentives could lead
RECs to make poor decisions. RECs
should focus on substantive questions
about the likely attitude of recipients to
the activity being incentivized, the degree
of recipient familiarity with that activity,
how risks and benefits are distributed, and
whether the incentive raises concerns
about fairness or justice. We explore these
issues in detail below.
Types of Payments and
Incentives
It is common practice in clinical and
public health research to pay participants
for expenses incurred as a result of
research participation. Payments as reim-
bursement for expenses like travel costs or
parking related to research participation
are not generally regarded as ethically
problematic. There is, however, a signifi-
cant literature on how to fairly calculate
payments as compensation for time and
effort [10–12]. Some jurisdictions and
institutions also require insurance arrange-
ments so that participants can receive
needed care if they are harmed as a result
of participation. In each of these cases the
goal is to ensure that recipients do not
have to incur a financial or material loss as
a result of research participation. More
controversial, are incentives for research
participation: cash payments, prizes, or
other material benefits provided for the
purpose of encouraging recipients to agree
to participate in research (recruitment) or
to continue their participation until the
study is completed (retention).
Different from all the above are incen-
tives for health promotion: cash payments,
gift cards, vouchers, prizes, or other
material benefits provided to encourage
recipients to utilize or adhere to a health
intervention, care plan, or behavior mod-
ification activity. The goal is to use the
incentive as an intervention intended to
produce better health outcomes for indi-
vidual recipients or better public health
outcomes for communities.
When the efficacy of using incentives to
promote health benefits is tested in
research, some study participants are
provided with incentives for health pro-
motion. In this case, RECs may be
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the intention of promoting a specific
healthy behavior might also act as an
inducement to participate in the study.
Our claim is that, even in such cases,
ethical judgments should be based on
specific factors (discussed below) that
determine whether the use of a specific
financial incentive creates a moral prob-
lem, and how significant that problem is.
Incentives Sometimes Promote
Autonomy
A common concern among RECs is
that particularly attractive incentives for
research participation, such as large sums
of money or difficult-to-obtain medical
care, might constitute an undue induce-
ment. If incentives cause recipients to
focus myopically on attaining the incentive
without attending to other salient aspects
of the decision, such as associated risks and
burdens, then the recipient’s choice would
not have the moral significance that comes
from the reflective application of their
considered values to the full range of
relevant information. In this case, incen-
tives might compromise the autonomy of
recipients by undermining the integrity of
their decision making process.
Whether incentives for research partic-
ipation compromise the integrity of the
recipient’s decision making process is
largely an empirical question. Recent
evidence seems to indicate that such
concerns are exaggerated [13–18].
Even if we put the empirical evidence
aside, however, this concern has the most
moral force in cases where incentives are
used to influence the choice of a recipient
who has not already considered the merits
of the available options, and where the
course of action being incentivized might
pose significant risks to the recipient or
involve actions or experiences to which the
recipient is averse [19,20]. Research often
uses procedures with which participants
are not familiar, such as blinding and
random allocation and administration of
interventions whose effects may be un-
known, and in some cases risks to
participants can be significant. In these
cases, RECs are rightly sensitive to the
potential for incentives for research par-
ticipation to adversely impact the autono-
my of participants.
In many cases, however, incentives for
health promotion are used to help recip-
ients bring about a personal change they
might already desire, through a means
with which they are already familiar. For
example, an obese person who is person-
ally committed to losing weight may
undertake weight-loss activities but have
difficulty adhering to the regimen [21].
The same may be true for smokers or
substance abusers trying to quit their
addiction [22]. In such cases, cash pay-
ments may be used, not to induce the
recipient to choose something they would
not otherwise choose, but to provide an
immediate positive reward for complying
with short-term steps necessary to effectu-
ate a longer term goal.
When the purpose of an incentive is to
enable recipients to overcome motivation-
al deficiencies in order to effectuate or to
maintain a life change to which they are
already committed, then, instead of un-
dermining or compromising autonomy,
incentives have the potential to be auton-
omy enhancing [23]. In such cases, the
usual prohibition against incentives that
are so large that recipients could not refuse
them might be both practically self-
defeating and of questionable moral value.
Whether particularly large or attractive
incentives are required to overcome an
agent’s inability to achieve a goal that they
personally endorse is an empirical ques-
tion [24]. Programs that rely on such
incentives may also be difficult to sustain
outside of the trial environment. But the
likely effect of an incentive on the
autonomy of recipients cannot be deter-
mined simply by assessing the incentive’s
magnitude or attractiveness.
Between explicit aversion and affirma-
tive commitment liea range ofless clear-cut
motivational states. Recipients may be
motivationally ambivalent, recognizing on
some level that an activity is desirable
withouthavinganactivedesireto engagein
that activity in practice. Alternatively,
recipients may face a motivational conflict,
recognizing the importance of several
activities or goals that compete for their
time and attention. For instance, a patient
may desire the long-term health effects of
taking a maintenance medication, but may
also want to avoid the side effects of
continued use. In the context of interna-
tional development, parents may want to
Summary Points
N Advances in behavioral economics are driving efforts to use material or financial
incentives to promote health-related behavior in international development,
public health, and clinical medicine.
N Current ethical frameworks for human research assume that material or
financial incentives are provided to participants either as compensation for their
time and expenses, or as an inducement to participate in research.
N We argue that some common concerns about using incentives to increase
participation in research, such as that attractive incentives will undermine
participant autonomy, are misplaced when incentives are used to overcome
economic obstacles or a lack of effective motivation, and when recipients are
incentivized to engage in health-related behaviors or practices with which they
are already familiar and which they regard as beneficial or worthwhile.
N We offer additional guidance to research ethics committees aimed at improving
the evaluation of research in which incentives are used as an intervention
intended to promote healthy behavior.
Box 1. Context for This Paper
The authors serve as members of the Ethics Working Group (EWG) of the HIV
Prevention Trials Network (HPTN) (http://www.hptn.org/researchethics/ethics.
asp). The EWG provides ethics advice for research carried out by the HPTN.
The EWG decided to examine the ethical issues arising from the review of
research involving the provision of financial incentives for health for two reasons.
First, RECs do not routinely encounter the provision of financial incentives as a
health intervention, and there is a lack of guidance about this issue in existing
regulations. Second, cash incentives are being used in two ongoing HPTN trials:
(1) HPTN-065, a study being conducted in multiple sites in the US that, among
other aims, is looking to evaluate the efficacy of financial incentives in promoting
expanded HIV testing and linkage to care (http://www.hptn.org/research_studies/
hptn065.asp), and (2) HPTN-068, a study being conducted in South Africa to
determine whether the provision of cash transfers to young women and their
households, conditional on school attendance, reduces young women’s risk of
acquiring HIV (http://www.hptn.org/research_studies/hptn068.asp).
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the more immediate social and economic
benefits of keeping the child at work.
In cases where recipients have more
ambiguous attitudes toward an activity,
the ethical assessment of incentives hinges
on factors such as the recipient’s degree of
familiarity with the course of action being
incentivized, the distribution and signifi-
cance of the risks associated with the
activity, the nature and distribution of
the expected benefits, and whether the
program of providing such incentives is
equitable and sustainable.
There are many common goals that
people might want to accomplish but are
unable to maintain the motivation to do so,
such as losing weight, breaking addiction,
regularly attending school, and practicing
safe sex. But it is unlikely that many people
share a similar attitude toward research
participation. As a result, incentives for
research participation may raise ethical
concerns that do not arise for incentives
to promote healthy behavior. However,
knowing that a large incentive might be
attainable in a study of incentives for health
might induce some people to participate in
the research. Whether such an indirect
inducement to participate in research
would be sufficient to compromise the
integrity of the recipient’s deliberative
process is an empirical question. But the
significance of this concern depends on
whether the study itself poses significant
additional risks to participants and how
familiar participants are likely to be with
the nature and sources of those risks.
The Legitimacy of Influencing a
Decision
Sometimes REC concerns about undue
inducement relate to the legitimacy of
interfering with the recipient’s delibera-
tion. This concern is not that the incentive
causes the recipient to overlook or ignore
relevant facts. It is that the desire for the
incentive is so strong that it causes the
recipient to knowingly act in contraven-
tion of deeply held values or beliefs. In this
case, the decision reflects the influence of
an outside party more than the authentic
values of the recipient.
To constitute wrongful interference, in-
centives must be used to prompt recipients
to do something that is clearly not in their
best interest or to act in a manner that
they ought not. For instance, inducing
recipients to accept risks that are unrea-
sonably high reflects a lack of respect for
the recipients’ welfare. It might also be
wrong to induce a person to engage in an
activity or to accept a risk to which they
are averse because doing so constitutes a
failure to respect the recipient’s view of his
or her welfare interests. Finally, an incen-
tive might be viewed as wrongful because
it is exploitative, in that it takes unfair
advantage of a recipient’s vulnerable social
or economic position.
Some have argued that by ensuring that
research risks are reasonable, prospective
REC review significantly diminishes the
likelihood that incentives for research
participation will constitute wrongful inter-
ference [25]. Even with adequate review,
however, some worry that large incentives
for research participation can induce peo-
ple to hide information about conditions
that would exclude them from participation
if disclosed, and that would result in their
being exposed to elevated risk [26]. Others
worry about the legitimacy of using incen-
tives to overcome participant aversion to
research procedures that involve intrusion
into or intimate contact with people’s
bodies or disclosure of sensitive personal
information [19,20].
In many cases, however, incentives for
health promotion are offered to help
recipients achieve goals that they already
desire and from which they directly
benefit. In the development context, for
example, conditional cash transfers have
been used to promote school attendance,
improve nutrition, and increase the eco-
nomic power of women in order to
promote gender equality. When recipients
stand to benefit directly from such activ-
ities, and recipients are unlikely to be
averse to the goals they promote, provid-
ing financial incentives for health promo-
tion would not constitute wrongful inter-
ference. In such cases, even if the prospect
of receiving an incentive induces people to
enroll in a study of an incentive for health
promotion, it is difficult to see how that
could constitute wrongful interference.
More difficult questions arise when
incentives are used to overcome the
motivational indifference, conflict, or aver-
sion of recipients to activities that are most
likely to benefit others. In such cases,
RECs should consider the importance of
the health benefit in question and the
likely sources of people’s reticence. For
example, providing a financial incentive to
overcome indifference toward completing
the full course of treatment to patients who
experience symptomatic relief after only
partial completion may be a legitimate
means of inhibiting the development of
drug resistance in the population. This
may be true even if patients are averse to
completing the treatment course in order
to avoid side effects, as in the case of
tuberculosis treatment [27].
Distribution and Significance of
Risks and Potential Benefits
In addition to evaluating whether the
provision of an incentive for health promo-
tion is likely to undermine the integrity of
the recipient’s deliberative process, and
whether its use represents a legitimate
means of influencing recipient behavior,
RECs should pay careful attention to the
way that incentives affect the balance of
risks and potential benefits in a trial.
Current guidelines state that RECs
must ensure that risks to participants are
reasonable in light of potential benefits of
the research. These benefits may accrue
directly to research participants, but this
need not be the case [28]. Risks to
participants that are not offset by the
prospect of direct benefit to participants
themselves can still be justified if they have
been minimized and are necessary to
produce knowledge of sufficient social
value [7,9,10,29].
Ethical guidance about the provision of
incentives in research holds that financial
payments should not be treated as a
benefit of research participation that can
offset risks to participants. One concern is
that allowing incentives for research par-
ticipation to offset risks that participants
may encounter within a study would
create a mechanism by which almost any
risk or burden could be permitted. This
would not only pose extra danger to
participants, it would also potentially
undermine the integrity of the research
enterprise by practically eliminating the
only mechanism by which RECs can
address the social value of research as a
knowledge-generating activity [29]. Re-
search whose social value is insufficient to
redeem the risks that it poses to partici-
pants could nevertheless be approved by
providing sufficiently high payments to
research participants. At the extreme, this
could result in trials being completed that
have little direct value to participants and
little or no social value either. Even if
participants would stand to profit from
receiving the incentive, conducting trials
that lack social value undermines the
social mission of the research enterprise.
When research examines incentives for
health promotion, the incentives are a core
component of the study intervention. It
would be difficult, therefore, to justify the
prohibition against treating them as a
benefit during REC review. In the context
of international development, for example,
incentives such as cash transfers or the
provision of food coupons are used to
overcome economic deprivations that
prevent impoverished individuals from
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such as traveling to a health care center to
receive childhood vaccinations, remaining
in school, or eating an enriched diet.
Receiving the cash or the food in such
cases appears to be a direct benefit of the
program.
Nevertheless, RECs should be careful
when weighing the significance of the
monetary or material benefit conferred
from receiving an incentive for health
promotion, especially in cases when the
incentive is used to overcome recipient
aversion to risks associated with the
activity being incentivized. In particular,
if the benefits of achieving the incentivized
goal for the individual, or for the larger
community, are not sufficient to justify the
risks associated with a trial, then the
provision of material incentives to pro-
mote those goals should not be treated as a
sufficiently significant additional benefit to
alter the unfavorable risk–benefit ratio of
the trial as a whole.
RECs should also consider whether
providing material incentives will nega-
tively affect the risk–benefit profile of an
activity. For example, if incentives can be
easily linked to a treatment program or
research protocol, they might reveal sen-
sitive information that increases the risk
that recipients will suffer adverse social
consequences. Similarly, in resource-poor
settings the knowledge that someone is the
recipient of a cash transfer may make that
person a target for robbery or assault. The
use of incentives in programs to enhance
gender equality may also place female
recipients at elevated risk of violence if
male community members seek to rein-
force operant social norms with violence.
Some claim that inducing people to
engage in a health-promoting activity via
the motive of profit might ‘‘crowd out’’
whatever intrinsic motivation the recipient
might have for engaging in that activity
[30–32]. Similarly, financial incentives
might promote expectations of financial
dole-outs for all research projects and/or
health interventions, irrespective of the
scientific merit of using incentives in those
cases. Another concern is that financial
incentives invite strategic behavior in
which some individuals attempt to game
the system.
RECs should evaluate the plausibility of
predictions about these risks in light of the
most current empirical findings, and
research should seek to evaluate the
degree to which such risks materialize in
actual practice.
Fairness and Social Justice
Several issues discussed above are
tightly connected to considerations of
fairness and justice. For example, the
risk–benefit profile of a trial is an impor-
tant moral concern in part because the
welfare of participants is itself of funda-
mental moral import. But it is also
important for ensuring that the research
enterprise reflects fair terms of social
cooperation, and merits the trust and
support of the myriad stakeholders who
contribute to its ability to serve the
common good [33]. It should not be the
case, for example, that risks are primarily
borne by the disadvantaged or socially
marginalized while the benefits of innova-
tion accrue to those who are already
comparatively advantaged [6].
Although the prospect that financial
incentives could be used to improve health
outcomes is an attractive hypothesis in a
variety of domains, careful consideration
must be given to the sustainability of such
interventions. Because communities and
health systems may differ in what kind of
health interventions they can deploy on a
sustainable basis, application of the same
moral standards across communities may
yield different assessments of the ethics of
conducting the same trial. In particular,
investigating the merits of an intervention
involving financial incentives may repre-
sent a poor use of scarce resources in
communities that could not deploy the
intervention on a sufficient level to achieve
the relevant health objective.
A lack of relevance to the health needs of
the host community may also affect the
risk–benefit assessment of a trial. In part, as
the social value of the trial decreases, it
becomes more difficult to justify risks to
participants that are not offset by the
prospect of direct benefit. There is also
evidence that introducing and then remov-
ing a material incentive for an activity can
crowd out existing motivation for engaging
in that activity [34,35]. For this reason,
even when the provision of financial
incentives is sustainable in a population,
careful consideration should be given to the
plan for terminating research and rolling
out the associated intervention.
When research is relevant to the health
needs of the host community, participating
in and supporting the research enterprise
can be seen as a way of contributing to an
important public good [33]. When signif-
icant disparities exist between research
sponsors and host communities, these
features of responsiveness create the foun-
dation for a collaborative partnership in
which all stakeholders can be seen as the
moral equal of the others. Alternatively, if
recipients view incentives as a mechanism
Box 2. Policy Recommendations for REC Review of Research
Involving Incentives for Health Promotion
1. Before considering the amount or potential attractiveness of an incentive, RECs
should consider the attitude of recipients to the activity being incentivized and
the degree of recipient familiarity with that activity.
2. We propose that concerns around the potential for incentives to undermine
recipient autonomy are misplaced when incentives are used to overcome
economic obstacles or a lack of effective motivation, and when recipients are
incentivized to engage in health-related behaviors or practices with which they
are already familiar and which they regard as beneficial or worthwhile.
3. It may be appropriate to treat the receipt of a financial or material incentive as a
benefit when reviewing research in which the incentive is itself a component of
the health intervention. However, if the benefits of achieving the incentivized
goal for the individual, or for the larger community, are not sufficient to justify
the risks associated with a trial, then receiving the incentive should not be
treated as a sufficiently significant additional benefit to alter the unfavorable
risk–benefit ratio of the trial as a whole.
4. RECs should require researchers to provide an evidence-based rationale for
predicting that the provision of an incentive will encourage the intended health
behavior and not adversely affect the willingness of participants or community
members to engage in that behavior. This rationale should also assess the likely
effects on participants and communities of the withdrawal of the incentive
during or at the conclusion of the study. Where possible, studies should gather
the data necessary to evaluate the accuracy of this rationale.
5. RECs should ensure, as far as possible, that the use of incentives to promote
healthy behavior could be sustained in the context where research is conducted
and would not represent an unreasonable use of scarce health resources.
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advance the interests of those offering the
incentive, then incentives can inhibit
compliance and crowd out intrinsic moti-
vation [32]. When clearly linked to health
or development goals that can be seen as
empowering recipients, such incentives are
more likely to encourage crowding in of
pro-health behaviors.
Finally, monetary or material incentives
can themselves have a direct impact on the
distribution of opportunities in a commu-
nity, at least to the extent that the
incentive increases the basket of resources
available to recipients. In some cases, this
can help to mitigate larger social inequal-
ities that may disadvantage poor or
marginalized populations and reduce eco-
nomic pressures that lead impoverished
individuals to engage in high-risk behav-
iors (such as the reliance of adolescent girls
on older men who promise to provide
them with economic support in return for
sexual favors, which makes them suscep-
tible to exploitation and HIV infection).
Nevertheless, when incentives for health
promotion are evaluated in trial designs
that involve the use of a non-incentive
control arm, care must be taken to ensure
that the research does not generate or
exacerbate objectionable inequalities in
the host community.
Conclusion
Whether paying people to engage in pro-
health behaviors represents an effective,
sustainable, and cost-effective tool for
promoting individual and public health is
an important research question. When
incentives are used to encourage utilization
of, or compliance with, established means
of producing individual or public health
benefits and when it is likely that recipients
are already favorably disposed to these
goals, then traditional concerns about the
provision of incentives in research may be
misplaced, and even misguided. When
trials are more complex, involving multiple
interventions or interventions that are
unfamiliar or investigational, RECs need
to pay careful attention to the consider-
ations outlined above (Box 2).
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